Targazyme, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Los Angeles CA United States (2005)
Status: Left NME R&D (2021)

Organization Overview

First Clinical Trial
2012
NCT01471067
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Alternative names

American Stem Cell, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 1)

Lymphoma (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Neoplasms (Phase 1)

Preleukemia (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 9